Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 42098470 · doi:10.1007/s12272-026-01615-y
What was done
Systematic review and random-effects meta-analysis (PROSPERO CRD420261277032) of randomized controlled trials identified from PubMed, Embase, and Web of Science from inception to November 2025. The study evaluated GLP-1 receptor agonists versus controls on cognition, clinical severity, biomarkers, and adverse events in non-diabetic individuals with Alzheimer's disease, Parkinson's disease, or mild cognitive impairment, assessing outcomes against minimal clinically important difference thresholds.
What was found
Fourteen randomized controlled trials with 1,260 participants were included. For global cognition, GLP-1 receptor agonists produced a small statistically significant improvement (SMD 0.14, 95% CI 0.01 to 0.27; I² = 7%; high-certainty evidence), corresponding to a 1% probability of clinically important benefit. For verbal fluency, GLP-1 receptor agonists were associated with poorer performance (SMD -0.43, 95% CI -0.79 to -0.08; I² = 0%; high-certainty evidence). In the Parkinson's disease subgroup, depressive symptoms significantly improved (MD -2.09, 95% CI -3.99 to -0.20; I² = 0%), but remained below the threshold for clinical importance. Clinical severity, functional measures, and general Parkinson's-related outcomes did not reach statistical significance. Biomarker results were inconsistent across trials. GLP-1 receptor agonists significantly reduced weight and increased gastrointestinal adverse events and poor tolerability.
Why it matters
This review demonstrates that despite statistical significance on select cognitive and depressive endpoints, GLP-1 receptor agonists do not achieve clinically meaningful benefit in non-diabetic patients with neurodegenerative disease, while increasing gastrointestinal burden.
Limits
The total sample size across 14 trials was modest (1,260 participants divided across Alzheimer's disease, Parkinson's disease, and mild cognitive impairment). Specific treatment durations, dosing regimens, and longitudinal disease modification endpoints were not detailed in the abstract.
Cited by
- supports There are currently no meaningful disease-modifying treatments for neurodegenerative diseases like Alzheimer's and Parkinson's disease that address the underlying disease process.